Effectiveness of nirmatrelvir‐ritonavir on severe outcomes of COVID‐19 in the era of vaccination and Omicron: An updated meta‐analysis
S Ombelet, D Castanares‐Zapatero… - Journal of medical …, 2024 - Wiley Online Library
Nirmatrelvir‐ritonavir (NR) was approved to treat SARS‐CoV‐2 positive outpatients at high
risk of progression to severe disease, based on a randomized trial in unvaccinated patients …
risk of progression to severe disease, based on a randomized trial in unvaccinated patients …
Nirmatrelvir/ritonavir use and hospitalizations or death in a previously uninfected nonhospitalized high-risk population with COVID-19: a matched cohort study
AA Butt, P Yan, OS Shaikh, VB Talisa… - The Journal of …, 2024 - academic.oup.com
Objective To determine the association of nirmatrelvir/ritonavir (NMV/r) with hospitalization
or death within 30 days as compared with untreated controls previously uninfected and …
or death within 30 days as compared with untreated controls previously uninfected and …
Clinical Outcome and 7-Day Virological Clearance in High-Risk Patients with Mild–Moderate COVID-19 Treated with Molnupiravir, Nirmatrelvir/Ritonavir, or …
F Bai, T Beringheli, V Vitaletti, A Santoro, F Molà… - Infectious Diseases and …, 2024 - Springer
Introduction We compared the effectiveness and virological clearance (VC) at day 7 (T7)
post-treatment with molnupiravir, nirmatrelvir/ritonavir, and remdesivir in SARS-CoV-2 …
post-treatment with molnupiravir, nirmatrelvir/ritonavir, and remdesivir in SARS-CoV-2 …
Identifying Veterans Who Benefit From Nirmatrelvir-Ritonavir: A Target Trial Emulation
L Yan, D Bui, Y Li, N Rajeevan… - Clinical Infectious …, 2024 - academic.oup.com
Background Nirmatrelvir-ritonavir is recommended for persons at risk for severe coronavirus
disease 2019 (COVID-19) but remains underutilized. Information on which eligible groups …
disease 2019 (COVID-19) but remains underutilized. Information on which eligible groups …
COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina
HI Henderson, DA Wohl, WA Fischer… - Journal of …, 2024 - academic.oup.com
Background In the USA, nirmatrelvir/ritonavir is authorized for the treatment of mild-to-
moderate COVID-19 in patients at least 12 years of age, at high risk for progression to …
moderate COVID-19 in patients at least 12 years of age, at high risk for progression to …
Insights from a community-based survey on factors influencing acceptance and uptake of Paxlovid (nirmatrelvir and ritonavir) as a COVID-19 antiviral medication in …
Introduction Antiviral treatment can reduce the burden of COVID-19. But utilisation can be
suboptimal, even in a setting like Singapore where it is fully subsidized for those with …
suboptimal, even in a setting like Singapore where it is fully subsidized for those with …
Comparing Molnupiravir to Nirmatrelvir/Ritonavir (Paxlovid) in the Treatment of Mild-to-Moderate COVID-19 in Immunocompromised Cancer Patients
AJ Haddad, RY Hachem, M Moussa, Y Jiang… - Cancers, 2024 - mdpi.com
Simple Summary The results of previous studies may suggest that Nirmatrelvir/Ritonavir,
when evaluated against placebo controls, could potentially be more effective than …
when evaluated against placebo controls, could potentially be more effective than …
[HTML][HTML] Paxlovid™ reduces the incidence of pneumonia, hospitalization, and death in a cohort of COVID-19 patients from northeast Mexico
MEC Moll, AMS Martínez, M Wu, GN Floriano… - Journal of Infection and …, 2024 - Elsevier
Abstract Background Information on Paxlovid™ effectiveness must be monitored and
updated in real world scenarios. Our research question was what is the effectiveness of …
updated in real world scenarios. Our research question was what is the effectiveness of …
Nirmatrelvir and ritonavir combination against COVID‐19 caused by omicron BA. 2.2 in the elderly: A single‐center large observational study
C Chen, R Li, S Xing, L Cao, Y Qu, Q Lv… - Immunity …, 2024 - Wiley Online Library
Abstract Background Since coronavirus 2019 (COVID‐19) swept the world, a variety of novel
therapeutic and prevention strategies have been developed, among which nirmatrelvir …
therapeutic and prevention strategies have been developed, among which nirmatrelvir …
Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO …
I Gentile, A Giaccone, MM Scirocco, F Di Brizzi… - medRxiv, 2024 - medrxiv.org
Introduction Ritonavir-boosted nirmatrelvir (N/r) is an antiviral which targets the main viral
protease, administered to prevent the progression of SARS-CoV-2 infection in patients at …
protease, administered to prevent the progression of SARS-CoV-2 infection in patients at …